Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001971941 | SCV002199819 | uncertain significance | Brugada syndrome | 2021-08-20 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with SLMAP-related conditions. This variant is present in population databases (rs760182153, ExAC 0.003%). This sequence change replaces isoleucine with methionine at codon 241 of the SLMAP protein (p.Ile241Met). The isoleucine residue is weakly conserved and there is a small physicochemical difference between isoleucine and methionine. |
Ambry Genetics | RCV004671541 | SCV005167092 | uncertain significance | not specified | 2024-04-25 | criteria provided, single submitter | clinical testing | The p.I241M variant (also known as c.723A>G), located in coding exon 8 of the SLMAP gene, results from an A to G substitution at nucleotide position 723. The isoleucine at codon 241 is replaced by methionine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |